Neova Katılım Sigorta Achieves Strong Growth and Maintains Sector Leadership in 2025

Neova Katılım Sigorta reports strong 2025 growth, reinforcing its leadership and innovation in the participation insurance sector.

0 Yorum Yapıldı
Bağlantı kopyalandı!
Neova Katılım Sigorta Achieves Strong Growth and Maintains Sector Leadership in 2025

Placed Among the Top 10 Overall

According to the Turkish Insurance Association (TSB) data for December 2025, Neova Katılım Sigorta secured the 10th position in total premium generation. The firm raised its overall premium revenue from 19 billion 68 million TL in 2024 to 30 billion 714 million TL by the end of 2025. This reflected a nominal annual increase of 61.07% and a real growth rate of 23.06% adjusted for inflation. The company’s market share advanced from 2.27% to 2.51%.

Leader in the Surety Bond Segment

Within branch-specific analysis, the Surety category showed the highest market prominence for Neova Katılım Sigorta. The company recorded 187 million 260 thousand TL in premium production in 2025, ranking first in the industry. Its market share in this segment expanded from 10.19% to 16.60%, marking an annual premium increase of 63.35%.

Rapid Expansion in Motor Vehicle (Comprehensive) Insurance

In the Motor Vehicle (Comprehensive Insurance) segment, the company displayed performance exceeding the sector average. With a total premium of 6 billion 341 million TL, Neova Katılım Sigorta ranked 8th overall. The company’s premium growth recorded 80.61% year-over-year, corresponding to a real increase of 37.99%. The market share in this segment rose from 3.12% to 4.30%.

Performance Across Additional Branches

The company’s premium results for other essential categories were as follows:

Motor Vehicle Liability (Traffic): Neova Katılım Sigorta ranked 12th with total production of 13 billion 254 million TL, maintaining a market share of 4.28% and annual growth of 46.06%.

İlgili Haber  Anadolu Hayat Emeklilik posts strong results for 2025

Fire and Natural Disasters: In this category, the firm achieved 4 billion 44 million TL in premiums and saw market share improve by 50.19% to 2.43%, placing 12th.

General Losses: Generating 2 billion 607 million TL in this branch, the company attained a 62.83% growth rate, holding a market share of 2.33%.

Reklam 173Reklam 281Reklam 741Reklam 4Reklam 681

Yorum Yap

Benzer Haberler
SEDDK and EBRD collaborate on the digitalization of insurance supervision
SEDDK and EBRD collaborate on the digitalization of insurance supervision
Türkiye Agricultural Credit Cooperatives Union visits TARSİM
Türkiye Agricultural Credit Cooperatives Union visits TARSİM
TSEV management visits SEDDK
TSEV management visits SEDDK
Anadolu Sigorta transforms insurance through its collaboration with Trio Mobil
Anadolu Sigorta transforms insurance through its collaboration with Trio Mobil
Sompo Sigorta’s Business Bootcamp Certification Program Keeps Growing Strong
Sompo Sigorta’s Business Bootcamp Certification Program Keeps Growing Strong
2026 State-Supported Agricultural Insurance Tariffs and Guidelines Announced
2026 State-Supported Agricultural Insurance Tariffs and Guidelines Announced
En Güncel ve Doğru Haberler!
Sigorta Haber

Sigortahaber.com, sigorta sektöründeki en güncel haberleri, analizleri ve gelişmeleri tarafsız bir bakış açısıyla sunan bağımsız bir haber platformudur. Sigorta profesyonellerine, acentelere ve sektöre ilgi duyan herkese doğru, hızlı ve güvenilir bilgi sağlamayı amaçlıyoruz. Sigortacılıktaki yenilikleri, mevzuat değişikliklerini ve sektör trendlerini yakından takip ederek, okuyucularımıza kapsamlı bir bilgi kaynağı sunuyoruz.

2025 Sigorta Haber © Tüm hakları saklıdır. Sitemizde yer alan Ekonomi ve Finans kategorilerindeki içerikler yalnızca bilgilendirme amaçlıdır; herhangi bir yatırım tavsiyesi niteliği taşımaz. Sağlık ve Bilgi kategorisinde bulunan içerikler genel olarak yapay zekâ tarafından üretilmiş olup yalnızca bilgilendirme amacı taşır. Herhangi bir sağlık sorunu yaşıyorsanız, burada yer alan bilgileri esas almak yerine en kısa sürede uzman bir doktora başvurmanız önerilir.